Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps

TY - JOUR

T1 - Correspondence

T2 - The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps

AU - Klimek, L.

AU - Mullol, J.

AU - Reitsma, S.

AU - van Gerven, L.

AU - Maza-Solano, J.

AU - Lundberg, M.

AU - Becker, S.

AU - Bärhold, F.

AU - Gawlik, R.

AU - Sokolowska, M.

AU - Hagemann, J.

AU - Akdis, C.

AU - Hox, V.

AU - Toppila-Salmi, S.

AU - Adcock, I. M.

AU - Escribese, G. M.

AU - Palomares, O.

AU - Moreira, A.

AU - Bonadonna, P.

AU - Ollert, M.

AU - Bousquet, J.

AU - de Corso, E.

AU - Shamji, M.

AU - Jaen, M. J.Torres

AU - Arasi, S.

PY - 2026/7

Y1 - 2026/7

UR - https://www.scopus.com/pages/publications/105036652345

UR - https://pubmed.ncbi.nlm.nih.gov/42033170/

U2 - 10.1111/all.70366

DO - 10.1111/all.70366

M3 - Letter

C2 - 42033170

AN - SCOPUS:105036652345

SN - 0105-4538

VL - 81

SP - 2568

EP - 2570

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 7

ER -